Respiratory

The Respiratory Department at St James’s hospital  run a number of both investigator-led and industry centered drug trials in respiratory in conjunction with the CRF.

Current Trials & Studies
Study Name Study TitleStudy TypeSponsorSponsor Type
Insmed (ASPEN)A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, MultiCenter Study to Assess the Efficacy, Safety, and Tolerability of INS1007 Administered Once Daily for 52 Weeks in Subjects with Non-CysticFibrosis Bronchiectasis Clinical Trial (2020-003688-25) (NCT04594369) InsmedCommercial: Industry
Thoracic Biobank Estbalishment of a Thoracic Biobank to use in molecular and Cellular Studies Prospective Cohort St. James's Foundation Non-commercial: Hospital
MA39297An international trial to characterize the disease behaviour of idiopathic pulmonary fibrosis and interstitial lung disease during the peri-diagnostic periodClinical Trial (NCT03261037)F Hoffmann- La Roche LtdCommercial: Industry
BAL dccrAirway Gene Expression Profiling and Immune Responses to Lung Disease (BAL)Observational-non invasiveN/ANon-commercial: Academic
Past Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
LusterA 52 week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthmaClinical Trial (NCT02555683) (2015-002553-35)Novartis Pharma UK LtdCommercial: Industry
GALACTIC-1A randomized, double-blind, multicentre, parallel, placebo-controlled study in patients with idiopathic pulmonary fibrosis (IPF) investigating the safety and efficacy of TD139, a dry powder, inhaled galectin-3 inhibitorClinical Trial (NCT03832946) (2018-002664-73) Galecto Biotech ABIndustry
CrystalCrystal - A prospective, multicentre, 12 week, randomized open label study to evaluate the efficacy and safety of glycopyrronium (50 microgrms o.d.) or indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 micrograms o.d.) regarding symptoms and health status in patients with moderate chronic obstructive pulmonary disease (COPD) switching from treatment with any standard COPD regimenClinical trial (NCT01985334) NovartisIndustry
PalladiumA multi-centre, randomised, 52 week treatment, double-blind, triple-dummy, parallel-group study to assess the efficacy and safety of QMF149 compared with mometason furoate in patients with asthmaClinical trial (NCT02554786) Novartis Pharma UK LtdIndustry
IPF/Sarcoidosis IPF/Sarcoidosis (DCCR) Observational with radiology or blood tests DCCR Non-commercial: Academic
IGRA IGRA (DCCR) Observational with radiology or blood tests HSE - Health Protection Surveillance Centre Non-commercial: Academic
INCA Inhaler Compliance in Asthma (INCA) Medical device study (NCT01529697) Health Research Board Non-commercial: Academic
SPICE III A Prospective Multicentre RCT of Early Goal Directed Sedation Compared with Standard Care in Mechanically Ventilated Patients in Intensive Care Prospective Cohort (NCT01728558) ICU Network Non-commercial: Hospital